Last reviewed · How we verify
Liraglutide + metformin
Liraglutide stimulates insulin secretion via GLP-1 receptor activation while metformin reduces hepatic glucose production and improves insulin sensitivity, together lowering blood glucose in type 2 diabetes.
Liraglutide stimulates insulin secretion via GLP-1 receptor activation while metformin reduces hepatic glucose production and improves insulin sensitivity, together lowering blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Liraglutide + metformin |
|---|---|
| Also known as | Victoza 6 mg/ml solution and Glucophage tablets, LIME |
| Sponsor | University Medical Centre Ljubljana |
| Drug class | GLP-1 receptor agonist + biguanide combination |
| Target | GLP-1 receptor; metformin targets mitochondrial glycerophosphate dehydrogenase |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | FDA-approved |
Mechanism of action
Liraglutide is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion and slows gastric emptying. Metformin is a biguanide that decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity. The combination provides complementary mechanisms to reduce hyperglycemia.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Headache
- Hypoglycemia
Key clinical trials
- Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome (PHASE3)
- Liraglutide Effect in Atrial Fibrillation (PHASE4)
- LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes (NA)
- Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Metabolic Surgery for Atrial Fibrillation Elimination (PHASE4)
- Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control (PHASE4)
- HbA1c Variability in Type II Diabetes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liraglutide + metformin CI brief — competitive landscape report
- Liraglutide + metformin updates RSS · CI watch RSS
- University Medical Centre Ljubljana portfolio CI